GET DAILY SIGNALSVolitionRx (VNRX) Reports +157% Revenue Growth in Q3 2026 as Losses Narrow
Key Takeaways
- VolitionRx reported third-quarter 2026 revenue of approximately $1.6 million, up 157% from $0.6 million in the same period a year earlier.
- Operating loss narrowed 35% to $3.3 million, while net loss declined to $3.8 million from $5.4 million in the prior-year quarter.
- Operating expenses fell 14% year over year, reflecting an ongoing cost-reduction program that has cut headcount by 28%.
- The company repaid $7.5 million of convertible notes early and ended the quarter with roughly $2.4 million in cash.
- Commercial momentum continued through new and expanded partnerships, including a Letter of Intent with Missionpharma and advancing collaborations with Sysmex and Werfen.
Earnings Context and Why It Matters
VolitionRx Limited is a clinical-stage epigenetics company developing blood-based diagnostic tests, centered on its Nu.Q platform for cancer and sepsis detection. The third quarter of 2026 matters because it offers the clearest evidence yet of whether the company can convert its scientific and partnership progress into a more sustainable financial profile. In recent periods, revenue has remained modest and lumpy, driven by deferred revenue recognition and timing of projects, while operating losses have persisted. Against that backdrop, investors are watching whether cost discipline, early debt reduction, and a growing pipeline of licensing discussions can narrow losses and extend the company's cash runway as it pursues commercialization. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Breaking Down the Reported Results
For the third quarter ended September 30, 2026, VolitionRx reported revenue of approximately $1.6 million, an increase of 157% compared with $0.6 million in the third quarter of 2025. Management attributed the growth primarily to increased recognition of deferred revenue.
Operating expenses declined 14% year over year, reflecting savings from the company's cost-reduction program, which included a 28% reduction in headcount compared with the prior-year period. As a result, the operating loss narrowed to $3.3 million, a 35% improvement from $5.1 million a year earlier.
Net loss for the quarter was $3.8 million, including about $0.4 million in non-cash charges tied to convertible notes, compared with a net loss of $5.4 million in the third quarter of 2025. The company also strengthened its balance sheet during the quarter, raising approximately $5.2 million in net proceeds through an at-the-market (ATM) equity facility and using those funds to retire the remaining $7.5 million of convertible note debt early.
Market Reaction and Investor Sentiment
Investor sentiment around VolitionRx heading into this report has been shaped by tension between promising scientific data and persistent financial constraints. The company has announced high-profile collaborations and peer-reviewed clinical results, but revenue remains small and the stock is thinly traded, leaving shares sensitive to both cash-burn concerns and milestone announcements.
The narrowing of losses, early repayment of convertible notes, and 157% revenue growth are likely to be read positively by investors focused on the company's path toward commercialization. At the same time, the limited absolute cash position and the company's stated need for additional funding remain key considerations that could temper enthusiasm. Broader sentiment will also depend on progress in converting active licensing discussions into signed agreements with upfront milestone payments.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors will be watching whether VolitionRx can translate its scientific momentum into recurring revenue. The company expects to submit its French reimbursement application for Nu.Q Lung Cancer during the current quarter, a step that could support routine clinical use and future geographic expansion.
Licensing discussions remain the central catalyst. Management has said it is in active negotiations with several major liquid biopsy and diagnostic companies around its Capture-Seq technology, targeting Multi-Cancer Early Detection (MCED) and Minimal Residual Disease (MRD) opportunities with large addressable markets. The timing and size of any signed agreement will be closely monitored.
On the financial side, cost discipline and cash runway stay in focus. The company has reduced headcount and retired its convertible notes, but it has also flagged the need for additional capital, making the pace of any future equity raises and their dilutive effect an important watch item. In the veterinary segment, the anticipated publication of the feline lymphoma study could unlock a $5 million milestone payment, while the DETECSEPS program in France provides a near-term clinical catalyst for the sepsis pillar. From what I see, these milestones could be pivotal in the coming quarters.
Using AI Tools for Deeper Analysis
When evaluating companies like this, I find it helpful to cross-reference results with broader market tools. One resource I turn to regularly is Tickeron’s AI Screener, which allows me to filter for similar names based on fundamentals, patterns, and performance metrics to gain additional perspective on potential comparables and trends.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
VNRX's RSI Indicator ascending out of oversold territory
The RSI Indicator for VNRX moved out of oversold territory on October 26, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 35 similar instances when the indicator left oversold territory. In 26 of the 35 cases the stock moved higher. This puts the odds of a move higher at 74%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +5.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where VNRX advanced for three days, in 146 of 199 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 46 cases where VNRX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VNRX as a result. In 90 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VNRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
VNRX broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for VNRX entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.183) is normal, around the industry mean (4.142). P/E Ratio (-0.051) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.767) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 66 (best 1 - 100 worst), indicating fairly steady price growth. VNRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VNRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a development stage life sciences company
Industry MedicalNursingServices
Advertisement